Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 9/20 | 0.54 |
| ▸ | ANPEP | P15144 | 7/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.54 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818458 | 1.00 | LAP3 (0.54) | LAP3ANPEPERAP1DNPEPALDH1A1 | |
| SCHEMBL14818457 | 1.00 | LAP3 (0.54) | LAP3ANPEPERAP1DNPEPALDH1A1 | |
| SCHEMBL14818454 | 1.00 | LAP3 (0.54) | LAP3ANPEPERAP1DNPEPALDH1A1 | |
| SCHEMBL14818456 | 1.00 | LAP3 (0.54) | LAP3ANPEPERAP1DNPEPALDH1A1 | |
| SCHEMBL14818494 | 0.83 | LAP3 (0.58) | LAP3ANPEPERAP1ALDH1A1TDP1 | |
| SCHEMBL14818503 | 0.83 | LAP3 (0.58) | LAP3ANPEPERAP1ALDH1A1TDP1 | |
| SCHEMBL14818504 | 0.83 | LAP3 (0.58) | LAP3ANPEPERAP1ALDH1A1TDP1 | |
| SCHEMBL14818495 | 0.83 | LAP3 (0.58) | LAP3ANPEPERAP1ALDH1A1TDP1 | |
| SCHEMBL14818496 | 0.83 | LAP3 (0.58) | LAP3ANPEPERAP1ALDH1A1TDP1 | |
| SCHEMBL14818507 | 0.81 | LAP3 (0.42) | LAP3ANPEPERAP1DNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492466-B2 | Beta-hydroxy-gamma-aminophosphonates for treating immune disorders | NUCITEC S.A. DE C.V. (MX) | 2016-11-15 | — | — | US | disclosed |
| US-20140107079-A1 | Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders | Nucites S.A. de C.V. (MX) | 2014-04-17 | — | — | US | disclosed |
| US-8536362-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2013-09-17 | — | — | US | disclosed |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107079-A1 | Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders | IFNG, HPGDS, AASDHPPT | LAP3 661/4885ANPEP 295/4885ERAP1 223/4885 |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | LAP3 636/4885ANPEP 322/4885ERAP1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.